

29 August 2008

Produced and issued by: ABN AMRO Equities Australia Ltd

Mesoblast

FY08: spinal shock

MSB's product has statistically significant higher fusion rates in anterior cervical interbody operations compared to a competitor. We believe the competitor's FY08 cervical fusion sales were cA\$325m, but has recently been forced to exit the market.

Change of target price

Buy


Target price
A\$1.50 (from A\$1.30)

Price
A\$1.280

Short term (0-60 days)
n/a

Price performance

	(1M)	(3M)	(12M)
Price (A\$)	1.10	0.74	1.60
Absolute %	16.4	74.1	-20.0
Rel market %	15.4	98.6	-1.3
Rel sector %	11.7	73.3	-13.8



Market capitalisation
A\$146.19m (US\$125.45m)

Average (12 mnth) daily turnover
A\$0.10m (US\$0.09m)

RIC: MSB.AX, MSB AU
Priced at close of business 29 Aug 2008.
Source: Bloomberg

Analysts

Dr David Stanton

Zara Lyons

Matthew Nicholas

ABN AMRO Equities Australia Ltd, ABN
84 002 768 701, AFS Licence 240530
Level 29, ABN AMRO Tower, 88 Phillip
Street, Sydney NSW 2000, Australia

<http://www.abnamroresearch.com>

Key forecasts

	FY07A	FY08A	FY09F	FY10F	FY11F
EBITDA (A\$m)	-7.90	-8.69	-9.07 ▲	-9.86 ▼	7.16 ▲
Reported net profit (A\$m)	-8.73	-10.1	-10.6	-11.1 ▼	3.38 ▲
Normalised net profit (A\$m) ¹	-8.73	-10.1	-10.6	-11.1 ▼	3.38 ▲
Normalised EPS (c) ¹	-8.20	-8.81	-8.61	-8.03 ▼	2.36 ▲
Normalised EPS growth (%)	-7.61	7.45	-2.31	-6.65	n/a
Dividend per share (c)	0.00	0.00	0.00	0.00	0.00
Dividend yield (%)	0.00	0.00	0.00	0.00	0.00
Normalised PE (x)	n/m	n/m	n/m	n/m	54.3
EV/EBITDA (x)	n/m	n/m	n/m	n/m	15.1
Price/net oper. CF (x)	-16.7	-27.3	-19.6 ▼	-20.9 ▼	25.0 ▲
ROIC (%)	-135.7	-73.0	-53.3	-71.4	55.3

Use of ▲ ▼ indicates that the line item has changed by at least 5%.

1. Pre non-recurring items and post preference dividends

Accounting Standard: IFRS

Source: Company data, ABN AMRO forecasts

year to Jun, fully diluted

FY08 result - higher-than-expected interest income

MSB posted an NPAT of -A\$10.1m for FY08, with a loss below our forecast of -A\$10.4m due to higher-than-expected interest income. We believe MSB has sufficient cash (A\$14.1m in FY08) to fund its clinical programme for the next one to two years.

A new cervical spine opportunity

Major recent news relates to a new indication for MSBs osteoinductive adult mesenchymal precursor cells (MPCs). MSB recently issued data showing that MSB's MPCs achieved a statistically significant improvement in cervical fusion rates compared to Medtronic's osteoconductive bulking agent (MasterGraft Granules). Given the recent issues with Medtronic's osteoinductive Recombinant Human Bone Morphogenic protein (rhBMP) product (also used in cervical fusion operations) we believe a significant opportunity exists with MSB's MPCs being potentially useful over the medium term in anterior cervical interbody fusion operations.

MSB's MPCs may address the gap in the market for cervical fusion

In July 2008, the US FDA issued a statement that the safety and effectiveness of rhBMP in the cervical spine had not been demonstrated and these products were not approved by FDA for this use. We believe the anterior interbody cervical spine fusion market for BMPs is worth cUS\$325m. As a result of the FDA decision, we believe there is currently no synthetic bone graft approved for anterior interbody cervical spine fusions. Medium-term, MSB's MPCs may address this gap in the market.

Buy rating maintained, target price A\$1.50

The major changes to our forecasts have been: 1) we believe MSB will get its product to market in FY11 (previously 2HFY10) - hence we believe MSB will not be cash flow positive until FY11; and 2) given the anterior cervical interbody fusion opportunity, we believe initial sales of MSB's cells will be greater, and have updated our forecasts accordingly. As a result of changes to forecasts, our DCF valuation and 12-month target price have increased by 15.4% to A\$1.50 per share.

Important disclosures can be found in the Disclosures Appendix.

The result

MSB posted an EBIT of -\$8.8m for FY08, with a loss below our forecast of A\$9.1m. At the NPAT level, MSB reported a loss of A\$10.1m, with a loss below our forecast of A\$10.4m, due to higher-than-expected interest income. The FY08 net operating cash outflow was A\$5.4m, compared to our forecast of A\$8.8m. Following the recent share placement, MSB has sufficient cash (A\$14.1m in FY08) to fund its clinical programme for the next one to two years. The changes to our forecasts are shown in the following table. The major changes to our forecasts have been: 1) we now believe MSB will get its product to market in FY11 (previously 2HFY10) – hence we now believe MSB will not be cash flow positive until FY11; and 2) given the anterior cervical interbody fusion opportunity, we believe initial sales of MSB’s cells will be greater, and have updated our forecasts accordingly.

Table 1 : Changes to forecasts

	FY08A			FY09F			FY10F		
	Fcast	Actual	Diff	Prev	Rev	Diff	Prev	Rev	Diff
EBIT (A\$m)	-9.1	-8.8	0.2	-9.7	-9.2	0.5	-1.6	-10.0	-8.5
NPAT (A\$m)	-10.4	-10.1	0.3	-10.9	-10.6	0.2	-2.5	-11.1	-8.7
EPS (c)	-9.6	-8.8	0.8	-9.1	-8.6	0.5	-1.9	-8.0	-6.2
DPS (c)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net op cash flow (A\$m)	-9.2	-6.2	3.0	-9.7	-8.8	0.9	3.1	-9.5	-12.6

Source: ABN AMRO estimates, company data


What is MSB?

Mesoblast (MSB) aims to capitalise on its patents that relate to the identification, extraction and culture of adult mesenchymal precursor cells (MPCs). MPCs are not fixed as to potential cell-line development (ie, they can become any type of cell, rather than being a mixture of committed types of cells). MSB hopes to develop treatments for bone/joint and cardiovascular diseases. Given the ageing of the western world population, we believe this is an attractive market segment. In the orthopaedic market, we believe the value of osteoinductive agents (MPCs are a sub-class of this market) will continue to grow.

1. Cervical spine opportunity

Major recent news related to a new indication for MSB’s MPCs. MSB has recently issued data that showed that MSB’s osteoinductive MPCs inserted in an interbody cage achieved a statistically significant improvement in cervical fusion compared to Medtronic’s Mastergraft osteoconductive bulking agent. We enclose the number of current and forecast cervical spine fusion procedures in the EU and US.

Chart 1 : Combined number of cervical spine fusion procedures (US and EU)



Source: ABN AMRO estimates, Frost & Sullivan

FDA issues a warning that Bone Morphogenic Proteins are not approved for use in the cervical spine

In July 2008, the US FDA issued a statement that the safety and effectiveness of osteoinductive rhBMP in the cervical spine had not been demonstrated and that these products were not approved by the FDA for this use. The FDA had received at least 38 reports of complications during the last four years regarding the use of rhBMP in cervical spine fusion. These complications were associated with swelling of neck and throat tissue, which resulted in compression of the airway and/or neurological structures in the neck. Some reports describe difficulty in swallowing, breathing or speaking. The mechanism of action is unknown, and characteristics of patients at increased risk have not been identified.

The Medtronic Biologics division, which includes rhBMP, generated sales of US\$815m in 2008. Given the recent issues with Medtronic's product, we believe a significant opportunity exists with MSB's MPC being potentially used over the medium-term in anterior cervical interbody fusion. We believe the anterior interbody cervical spine fusion market for BMPs is a cUS\$325m market, as c40% of total fusions are in the cervical region of the spine. As a result of the FDA decision, we believe there is currently no synthetic bone graft approved for anterior interbody cervical spine fusions. Longer term, MSB's MPCs may address this gap in the market.

MSB product – significant results in spinal fusion

MSB initiated trials at Monash University to determine the safety and efficacy profile of its MPCs in cervical fusion. 24 sheep were randomised to one of the four treatment arms: osteoconductive/osteoinductive autograft, osteoconductive bone graft substitute (Medtronic MasterGraft granules), and allogeneic osteoinductive Mesoblast cells at doses of 5 million or 10 million cells implanted in an FDA-approved interbody cage. The trial was completed in three months.

Significantly, no cell-related adverse events were noted throughout the study. Groups receiving either dose of MSB's allogeneic cells had earlier and more robust fusion than the other groups:

- **CT scanning:** By CT scan at three months, 9/12 cell-treated animals had continuous interbody bony bridging compared with only 1/6 autograft and 2/6 with bone graft substitute ($p=0.019$ and $p=0.043$ respectively);
- **X-rays:** Functional x-rays at three months showed that cell-treated subjects had significantly reduced flexion/extension at the C3/4 level compared with the other groups ($p=0.007$), indicating significantly superior fusion outcomes.

Interestingly, the numbers of cells used in the MPC arm of the trial were 7% and 13% of the number of cells previously suggested as the minimum number of cells required for fusion.

We believe the US FDA reimburses US\$5,000 per interbody level, and we believe MSB would be likely to only have 10 million cells per interbody treatment. We note that the majority of variable costs for MSB are related to the number of cells per treatment – hence if MSB can decrease the number of cells per treatment, then profit per treatment should increase.

MSB to move to Phase III trial in anterior interbody cervical spine fusion

Mesoblast believes that this clinical indication may provide an accelerated path to regulatory market approval of its product. Hence, MSB plans to pursue formal regulatory discussions regarding initiation of a Pivotal/Phase 3 clinical trial protocol for use of its MPC cells for cervical fusion. This is likely to start in 2HCY09, and is likely to involve 300 higher-risk anterior interbody cervical spine fusion patients (this group would include smokers and diabetics, who generally have lower rates of allograft fusion). The clinical end-point for the trial is likely to be a year after the trial is fully recruited.


What does this mean for MSB?

We believe there are two takeaways from this announcement:

- **Timeline for approval:** Should MSB receive approval from the FDA to progress to a Phase III clinical trial, we believe this may mean that MSB would enter the market earlier than expected. We forecast MSB will enter the market with its MPCs in FY11; and,

- **Should trials prove successful, then MSB may become an acquisition target for an orthopaedic company:** We continue to believe MSB is most likely to partner with an orthopaedic firm to take MPC to market. Should the technology continue to progress through clinical trials, we believe MSB may become an acquisition target for an orthopaedic company. The estimated market shares of the bone graft market are shown below.

Chart 2 : 2007 – estimated market shares of the bone graft market



Source: ABN AMRO

2. Other key outlook takeaways

- **Phase II clinical trials** – MSB has entered Phase II clinical trials for lumbar spinal fusion and long bone fractures. We assume an accelerated approval process from the US FDA as we believe MSB's product will be classified as a device rather than a pharmaceutical product;
- **Strong growth rates predicted in volume and pricing of bone-graft technology** – Our analysis of bone-graft technology suggests pricing for these products will remain strong, driven by a lack of supply in a market with high barriers to entry. Indeed, discussions with industry contacts suggest that in a revision joint replacement, a bone-graft substitute is the most expensive piece of equipment used. The current price is A\$10,000 for a 10cc vial, and up to two vials of bone-graft substitute may be used in a single revision joint replacement; and
- **Levels of cash** – As at 30 June 2008, MSB had a net cash position of A\$14.1m. Going forward, we believe the cash requirements will likely continue for MSB and may increase. At the rate of cash burn, and without further infusions of cash, this suggests MSB has enough cash to continue operations for the next 12-18 months. After that time, the company may conduct another capital raising or might have secured funding from a partner. Based on our current rate of cash burn, we have factored in MSB conducting a A\$20m equity raising in 2H09, and a A\$15m equity raising in FY10.

Buy rating maintained; target price A\$1.30

As a result of changes to forecasts, our DCF valuation and 12-month target price have increased by 15.4% to A\$1.50 per share. On an industry-wide basis, the chances of getting a product to market from the Phase II stage are in the order of 30%. Hence, we believe the risks that MSB will be unable get a product to market are not inconsiderable. MSB's patent position is strong, but we think the company is unlikely to be cash flow positive before FY11. Hence, we believe MSB is an opportunity for investors with a higher risk appetite.

Table 2 : Updated timeline and probability of MSB’s opportunities

Trial stage	Preclinical	Investigational New Drug application	Phase II trials	Clinical III trials
General time until cashflow	7 years+	5-7 years	3-5 years	1-2 years
General probability of product getting to market	c10%	c10-20%	c30%	c70%
Cost of trials	cA\$1m	cA\$2-3m	cA\$10m	cA\$50m
MSB products - indications and stages of development				
Spinal Fusion (cervical/lumbar)	→			
Long bone fractures	→			
Congestive Heart failure (via Angioblast)	→			
Heart attack (via Angioblast)	→			
Osteoarthritis knee	→			
Knee cartilage tears	→			
Peripheral arterial disease (via Angioblast)	→			
Other indications	→			

Source: Company data, ABN AMRO estimates

Model assumptions

The major components of our model for MSB are shown below:

- **Time on market** – in line with management commentary, we believe MSB will get its product to market in FY11 (previously 2HFY10). Hence, we now believe MSB will not be cash flow positive until FY11. However, given the anterior cervical interbody fusion opportunity, we believe initial sales will be greater, and have updated our forecasts accordingly;
- **Market size in FY11** – We assume the market size will be US\$1.35bn in FY11. At our assumed price per injection, this translates into about 190,000 injections.
- **Assumption for MSB market share** – We assume MSB’s orthopaedic product will gain 10% market share in FY11. This translates into c17,000 treatments. For FY11, we assume MSB will extract 50mLs of bone marrow from four donors, which translates into 17,284 treatments, equivalent to 9.1% market share.
- **Royalty assumptions** – We assume MSB will receive a 20% royalty rate on sales of its orthopaedic product. This is in line with our assumptions on royalty rates that have been recently negotiated between biotech companies and global pharmaceutical companies.
- **EBIT assumptions** – In line with most pharmaceutical companies, we assume MSB achieves a steady-state EBIT margin of about 20%.
- **Equity raising** – Given that we do not believe MSB will be cash flow positive until FY11, we believe there will be a need for a capital raising in FY10. We now assume a A\$15m equity raising in FY10.
- **Net interest balance** – This has been adjusted for new cash balances for the end of the period.
- **Number of shares** – This has been updated for period-end balances.
- **Target D/DE ratio** – We assume MSB will be wholly equity funded given it is not expected to generate a steady rate of positive net cash flow for several years. Accordingly we assume a target ratio of debt to debt plus equity of zero.

MSB – financial summary

Year to 30 Jun (A\$m)	AIFRS 2007A	AIFRS 2008A	AIFRS 2009F	AIFRS 2010F	AIFRS 2011F	Closing price (A\$)	1.30	Price target (A\$)	1.50	
Income statement						Valuation metrics				
Divisional sales	0.0	0.0	0.0	0.0	28.5	Preferred methodology	DCF	Val'n (A\$)	\$ 1.50	
Total revenue	0.7	0.0	0.2	0.2	28.7	DCF valuation inputs				
EBITDA	-7.9	-8.7	-9.1	-9.9	7.2	Rf	6.50%	10-year rate	6.50%	
Associate income	-1.7	-2.1	-2.1	-2.1	-2.1	Rm-Rf	4.50%	Margin	2.0%	
Depreciation	-0.1	-0.2	-0.2	-0.2	-1.4	Beta	1.50	Kd	8.50%	
EBITA	-8.0	-8.8	-9.2	-10.0	5.7	CAPM (Rf+Beta(Rm-Rf))	13.3%	Ke	13.2%	
Amortisation/impairment	0.0	0.0	0.0	0.0	0.0	E/EV*Ke+D/EV*Kd(1-t)		NPV cash flow (A\$m)	170.7	
EBIT	-8.0	-8.8	-9.2	-10.0	5.7	Equity (E/EV)	100.0%	Minority interest (A\$m)	0.0	
EBIT(incl associate profit)	-9.7	-11.0	-11.3	-12.1	3.6	Debt (D/EV)	0.0%	Net debt (A\$m)	-14.1	
Net interest expense	0.9	0.9	0.7	1.0	1.2	Interest rate	8.50%	Investments (A\$m)	0.0	
Pre-tax profit	-8.7	-10.1	-10.6	-11.1	4.8	Tax rate (t)	30.0%	Equity market value (A\$m)	184.8	
Income tax expense	0.0	0.0	0.0	0.0	-1.5	WACC	13.2%	Diluted no. of shares (m)	123.7	
After-tax profit	-8.7	-10.1	-10.6	-11.1	3.4			DCF valuation (A\$)	1.49	
Minority interests	0.0	0.0	0.0	0.0	0.0					
NPAT pre significant items	-8.7	-10.1	-10.6	-11.1	3.4	Multiples	2008A	2009F	2010F	2011F
Significant items	0.0	0.0	0.0	0.0	0.0	Enterprise value (A\$m)	135.5	123.9	117.4	111.5
Reported NPAT	-8.7	-10.1	-10.6	-11.1	3.4	EV/Sales (x)			7.8	3.9
						EV/EBITDA (x)	n/a	n/a	n/a	15.6
Cash flow statement	2007A	2008A	2009F	2010F	2011F	EV/EBIT (x)	n/a	n/a	n/a	19.5
EBITDA	-7.9	-8.7	-9.1	-9.9	7.2	PE (normalised) (x)	n/a	n/a	n/a	55.6
Change in working capital	0.0	0.0	0.3	0.3	0.4	PEG (normalised) (x)				
Net interest (pd)/rec	0.9	0.8	0.7	1.0	1.2					
Taxes paid	0.0	0.0	0.0	0.0	-1.5	At target price	2008A	2009F	2010F	2011F
Other oper cash items	0.0	0.0	0.0	0.0	0.0	EV/EBITDA (x)	n/a	n/a	n/a	18.6
Cash flow from ops (1)	-8.2	-5.4	-8.1	-8.5	7.4	PE (normalised) (x)	n/a	n/a	n/a	63.7
Capex (2)	-0.1	-0.1	-0.1	-0.1	-1.4					
Disposals/(acquisitions)	-3.9	-6.4	-0.2	0.0	0.0	Comparable company data (x)	2009F	2010F	2011F	
Other investing cash flow	-0.3	0.3	0.0	0.0	0.0	Alchemia	EV/EBITDA	-4.0	7.2	1.3
Cash flow from invest (3)	-4.3	-6.2	-0.3	-0.1	-1.4	Year to 30 Jun	EV/EBIT	-3.5	10.8	1.4
Incr/(decr) in equity	16.8	13.6	20.0	15.0	0.0		PE	-4.4	5.7	0.8
Incr/(decr) in debt	0.0	0.0	0.0	0.0	0.0		PEG	-1.3	1.6	0.2
Ordinary dividend paid	0.0	0.0	0.0	0.0	0.0	Tissue Therapies	EV/EBITDA	0.6	-3.2	-3.7
Preferred dividends (4)	0.0	0.0	0.0	0.0	0.0	Year to 30 Jun	EV/EBIT	0.6	-3.2	-3.7
Other financing cash flow	0.0	0.0	0.0	0.0	0.0		PE	-2.1	4.1	2.7
Cash flow from fin (5)	16.8	13.6	20.0	15.0	0.0		PEG			
Forex and disc ops (6)	0.0	0.0	0.0	0.0	0.0					
Incr/(decr) cash (1+3+5+6)	4.3	2.0	11.7	6.4	5.9	Per share data	2008A	2009F	2010F	2011F
Equity FCF (1+2+4)	-8.3	-5.5	-8.1	-8.6	5.9	No. shares	114.2	133.2	143.7	143.7
						EPS (cps)	-8.8	-8.6	-8.0	2.4
Balance sheet	2007A	2008A	2009F	2010F	2011F	EPS (normalised) (c)	-8.8	-8.6	-8.0	2.4
Cash & deposits	12.1	14.1	25.8	32.2	38.1	Dividend per share (c)	0.0	0.0	0.0	0.0
Trade debtors	0.5	0.1	0.1	0.2	0.2	Dividend payout ratio (%)	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	Dividend yield (%)	0.0	0.0	0.0	0.0
Investments	7.7	12.8	13.0	13.0	13.0	Growth ratios	2008A	2009F	2010F	2011F
Goodwill	0.0	0.0	0.0	0.0	0.0	Sales growth	na	na	na	90.5%
Other intangible assets	0.8	0.5	0.4	0.3	0.3	Operating cost growth	10.0%	4.3%	8.7%	116.4%
Fixed assets	0.2	0.2	0.2	0.2	0.2	EBITDA growth	10.0%	4.3%	8.7%	*MISSING
Other assets	0.0	0.1	0.1	0.1	0.1	EBITA growth	11.1%	4.2%	8.6%	*MISSING
Total assets	21.2	27.8	39.6	46.0	51.9	EBIT growth	11.1%	4.2%	8.6%	*MISSING
Short-term borrowings	0.0	0.0	0.0	0.0	0.0	EBIT NPAT growth (pre GW)	15.3%	5.8%	4.5%	-130.4%
Trade payables	0.7	1.6	1.9	2.3	2.7	Norm. NPAT growth	15.3%	5.8%	4.5%	-130.4%
Long-term borrowings	0.0	0.0	0.0	0.0	0.0	Norm. EPS growth (pre GW)	7.4%	-2.3%	-6.6%	*MISSING
Provisions	0.0	0.0	0.0	0.0	0.0	Norm. EPS growth	7.4%	-2.3%	-6.6%	*MISSING
Other liabilities	0.0	0.0	2.1	4.2	6.4					
Total liabilities	0.7	1.6	4.0	6.5	9.1	Operating performance	2008A	2009F	2010F	2011F
Preference shares						Asset turnover (%)	0.0	0.0	0.0	14.6
Hybrid equity	0.0	0.0	0.0	0.0	0.0	EBITDA margin (%)	na	na	na	25.1
Share capital	37.4	51.0	71.0	86.0	86.0	EBIT margin (%)	na	na	na	20.1
Other reserves	1.6	3.8	3.8	3.8	3.8	Net profit margin (%)	na	na	na	11.9
Retained earnings	-18.5	-28.6	-39.2	-50.3	-46.9	Return on net assets (%)	-33.8	-25.9	-25.4	13.4
Other equity	0.0	0.0	0.0	0.0	0.0	Net debt (A\$m)	-14.1	-25.8	-32.2	-38.1
Total equity	20.5	26.2	35.6	39.4	42.8	Net debt/equity (%)	-53.8	-72.4	-81.6	-89.0
Minority interest	0.0	0.0	0.0	0.0	0.0	Net interest/EBIT cover (x)	9.7	13.2	9.9	-4.7
Total shareholders' equity	20.5	26.2	35.6	39.4	42.8	ROIC (%)	-73.0	-53.3	-71.4	55.3
Total liabilities & SE	21.2	27.8	39.6	46.0	51.9					
						Internal liquidity	2008A	2009F	2010F	2011F
						Current ratio (x)	9.1	6.5	5.0	4.2
						Receivables turnover (x)	na	0.0	0.0	145.2
						Payables turnover (x)	na	5.2	4.7	8.6

Source: ABN AMRO estimates, company data

Recommendation structure

Absolute performance, short term (trading) recommendation: A Trading Buy recommendation implies upside of 5% or more and a Trading Sell indicates downside of 5% or more. The trading recommendation time horizon is 0-60 days. For Australian coverage, a Trading Buy recommendation implies upside of 5% or more from the suggested entry price range, and a Trading Sell recommendation implies downside of 5% or more from the suggested entry price range. The trading recommendation time horizon is 0-60 days.

Absolute performance, long term (fundamental) recommendation: The recommendation is based on implied upside/downside for the stock from the target price. A Buy/Sell implies upside/downside of 10% or more and a Hold less than 10%. For UK Small/Mid-Cap Analysis a Buy/Sell implies upside/downside of 10% or more, an Add/Reduce 5-10% and a Hold less than 5%. For UK-based Investment Funds research the recommendation structure is not based on upside/downside to the target price. Rather it is the subjective view of the analyst based on an assessment of the resources and track record of the fund management company. For listed property trusts (LPT) or real estate investment trusts (REIT) the recommendation is based upon the target price plus the dividend yield, ie total return.

Performance parameters and horizon: Given the volatility of share prices and our pre-disposition not to change recommendations frequently, these performance parameters should be interpreted flexibly. Performance in this context only reflects capital appreciation and the horizon is 12 months. Sector relative to market: The sector view relative to the market is the responsibility of the strategy team. Overweight/Underweight implies upside/downside of 10% or more and Neutral implies less than 10% upside/downside. Target price: The target price is the level the stock should currently trade at if the market were to accept the analyst's view of the stock and if the necessary catalysts were in place to effect this change in perception within the performance horizon. In this way, therefore, the target price abstracts from the need to take a view on the market or sector. If it is felt that the catalysts are not fully in place to effect a re-rating of the stock to its warranted value, the target price will differ from 'fair' value.

Distribution of recommendations

The tables below show the distribution of ABN AMRO's recommendations (both long term and trading). The first column displays the distribution of recommendations globally and the second column shows the distribution for the region. Numbers in brackets show the percentage for each category where ABN AMRO has an investment banking relationship.

Long Term recommendations (as at 29 Aug 2008)		
	Global total (IB%)	Asia Pacific total (IB%)
Buy	527 (4)	369 (0)
Add	0 (0)	0 (0)
Hold	367 (2)	216 (0)
Reduce	0 (0)	0 (0)
Sell	95 (0)	57 (0)
Total (IB%)	989 (3)	642 (0)

Source: ABN AMRO

Trading recommendations (as at 29 Aug 2008)		
	Global total (IB%)	Asia Pacific total (IB%)
Trading Buy	4 (0)	4 (0)
Trading Sell	1 (0)	1 (0)
Total (IB%)	5 (0)	5 (0)


Source: ABN AMRO

Valuation and risks to target price

Mesoblast (RIC: MSB.AX, Rec: Buy, CP: A\$1.280, TP: A\$1.500): Our valuation of MSB is based on a discounted cash flow model, from which we derive our target price. Upside risks include the faster-than-expected progression to production of MSB's MPC technology, while downside risks include the lack of scalability of the manufacturing process.

Mesoblast coverage data

Stock performance, recommendations and coverage (as at 28 Aug 2008)



Trading recommendation history (as at 29 Aug 2008)

Date	Rec	Analyst
	n/a	

Source: ABN AMRO

Dr David Stanton started covering this stock on 2 Aug 07
 New recommendation structure from 7 November 2005
 Source: ABN AMRO

Regulatory disclosures

Subject companies: MSB.AX

Global disclaimer

© Copyright 2008 ABN AMRO Bank N.V. and affiliated companies ("ABN AMRO"). All rights reserved.

This material was prepared by the ABN AMRO affiliate named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. The stated price of any securities mentioned herein is as of the date indicated and is not a representation that any transaction can be effected at this price. Neither ABN AMRO nor other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without ABN AMRO's prior express consent. In any jurisdiction in which distribution to private/retail customers would require registration or licensing of the distributor which the distributor does not currently have, this document is intended solely for distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by ABN AMRO Equities Australia Ltd (ABN 84 002 768 701, AFS Licence 240530), a participant of the ASX Group. Any report referring to fixed income securities is distributed in Australia by ABN AMRO Bank NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Brazil: This document was not elaborated by securities analysts registered at Comiss o de Valores Mobili rios - CVM. Investors resident in Brazil who receive this report should rely only on research prepared by research analysts registered at CVM. In addition to other representations contained in this report, research analysts who prepared this report state that the views expressed and attributed to them accurately reflect solely and exclusively their personal opinions about the subject securities and issuers and/or other subject matter as appropriate, having such opinion(s) been produced freely and independently from any party, including from The Royal Bank of Scotland or any of its affiliates.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and many not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact their own advisors.

EEA: This material constitutes "investment research" for the purposes of the Markets in Financial Instruments Directive and as such contains an objective or independent explanation of the matters contained in the material. Any recommendations contained in this document must not be relied upon as investment advice based on the recipient's personal circumstances. In the event that further clarification is required on the words or phrases used in this material, the recipient is strongly recommended to seek independent legal or financial advice.

Denmark: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Copenhagen Branch is subject to local supervision by Finanstilsynet, the Danish Financial Supervisory Authority. All analysts located in Denmark follow the recommendations from the Danish Securities Dealers Association.

Finland: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Helsinki Branch is subject to local supervision by Rahoitusarkastus, the Finnish Financial Supervision Authority.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, ABN AMRO Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong.

India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs") and Overseas Corporate Bodies ("OCBs"), predominantly owned by such persons or Persons of Indian Origin (PIO). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of ABN AMRO Asia Equities (India) Limited.

Italy: Persons in Italy requiring further information should contact ABN AMRO Bank N.V. Milan Branch.

Japan: This report is being distributed in Japan by ABN AMRO Securities Japan Ltd to institutional investors only.

Malaysia: ABN AMRO research, except for economics and FX research, is not for distribution or transmission into Malaysia.

New Zealand: This document is distributed in New Zealand to institutional investors by ABN AMRO Securities NZ Limited, an NZX accredited firm, and to retail investors by ABN AMRO Craigs Limited, an NZX accredited firm. ABN AMRO Craigs Limited and/or its partners and employees may, from time to time, have a financial interest in respect of some or all of the matters discussed.

Russia: The Russian securities market is associated with several substantial risks, legal, economic and political, and high volatility. There is a relatively high measure of legal uncertainty concerning rights, duties and legal remedies in the Russian Federation. Russian laws and regulations governing investments in securities markets may not be sufficiently developed or may be subject to inconsistent or arbitrary interpretation or application. Russian securities are often not issued in physical form and registration of ownership may not be subject to a centralised system. Registration of ownership of certain types of securities may not be subject to standardised procedures and may even be effected on an ad hoc basis. The value of investments in Russian securities may be affected by fluctuations in available currency rates and exchange control regulations.

Singapore: Any report referring to equity securities is distributed in Singapore by ABN AMRO Asia Securities (Singapore) Pte Limited (RCB Regn No. 198703346M) to clients who fall within the description of persons in Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations and Regulations 34 and 35 of the Financial Advisers Regulations. Any report referring to non-equity securities is distributed in Singapore by ABN AMRO Bank NV (Singapore Branch) Limited to clients who fall within the description of persons in Regulations 34 and 35 of the Financial Advisers Regulations. Investors should note that this material was prepared for accredited investors only. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations or Regulations 34 and 35 of the Financial Advisers Regulations should seek the advice of their independent financial advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents.

Sweden: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Stockholm Branch is subject to local supervision by the Swedish Financial Supervisory Authority.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by ABN AMRO Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

United Kingdom: All research is distributed by ABN AMRO Bank NV, London Branch, which is authorised by De Nederlandsche Bank and regulated by the Financial Services Authority for the conduct of UK business. The investments and services contained herein are not available to private customers in the United Kingdom.

UAE and Qatar: This report is produced by ABN AMRO N.V and is being distributed to professional and institutional investors only in the United Arab Emirates and Qatar in accordance with the regulatory requirements governing the distribution of investment research in these jurisdictions.

United States: Except for any documents relating to foreign exchange, FX or global FX, distribution of this document in the United States or to US persons is intended to be solely to major institutional investors as defined in Rule 15a-6(a)(2) under the US Securities Act of 1934. All US persons that receive this document by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities. Any US recipient of this document wanting additional information or to effect any transaction in any security or financial instrument mentioned herein, must do so by contacting a registered representative of ABN AMRO Incorporated, 101 Park Avenue, New York, N.Y. 10178, US, tel + 1 212 401 3200.

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP.

The Royal Bank of Scotland plc is authorised and regulated in the UK by the Financial Services Authority.

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at www.abnamroresearch.com.

Disclosures regarding companies covered by ABN AMRO group can be found on ABN AMRO's research website at www.abnamroresearch.com.

ABN AMRO's policy on managing research conflicts of interest can be found at <https://www.abnamroresearch.com/Disclosure/Disclosure.AspX?MI=5>.

Should you require additional information please contact the relevant ABN AMRO research team or the author(s) of this report.